ivarmacitinib

Protein Kinase Inhibitor

Also Known As:

SHR0302; SHR0302 base; cyclopenta(c)pyrrole-2(1H)-carboxamide, hexahydro-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-(methyl-7H-pyrrolo(2,3-d)pyrimidin-4-ylamino)-, (3a alpha,5 alpha,6a alpha)-; ivarmacitinib sulfate

Networked: 10 relevant articles (0 outcomes, 3 trials/studies)

Bio-Agent Context: Research Results

Inorganic Chemicals: 9
- Acids: 53217
  - Noncarboxylic Acids
    - Sulfur Acids
      - Sulfuric Acids: 4
        ivarmacitinib: 10
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfuric Acids: 4
      - ivarmacitinib: 10
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Sulfur Acids
    - Sulfuric Acids: 4
      - ivarmacitinib: 10

Experts

1.	Wei, Wei: 2 articles (10/2016 - 09/2016)
2.	Ding, Yangfeng: 1 article (11/2021)
3.	Dong, Xiuqin: 1 article (11/2021)
4.	Goh, Aik Han: 1 article (11/2021)
5.	Ji, Chao: 1 article (11/2021)
6.	Liu, Rongjun: 1 article (11/2021)
7.	Lu, Jianyun: 1 article (11/2021)
8.	Lu, Qianjin: 1 article (11/2021)
9.	Tao, Xiaohua: 1 article (11/2021)
10.	Wang, Rupeng: 1 article (11/2021)

Related Diseases

1.	Atopic Dermatitis (Atopic Eczema) 11/01/2021 - "The aim of this study was to investigate the efficacy and safety of SHR0302 in Chinese patients with moderate to severe atopic dermatitis. " 11/01/2021 - "Oral SHR0302 was effective and well tolerated in Chinese adult patients with moderate to severe atopic dermatitis. " 11/01/2021 - "Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial."
2.	Ulcerative Colitis 12/01/2022 - "Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study."
3.	Alopecia Areata 11/01/2023 - "A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata."
4.	Rheumatoid Arthritis 02/01/2023 - "SHR0302, a selective JAK1 inhibitor developed by Jiangsu Hengrui Pharmaceutical Co., was intended for the treatment of rheumatoid arthritis. " 01/01/2023 - "SHR0302 is a selective Janus kinase (JAK) 1 inhibitor under clinical investigation for the treatment of rheumatoid arthritis (RA). " 11/01/2022 - "SHR0302, as a novel Janus kinase (JAK) inhibitor 1, is used for treatment of rheumatoid arthritis (RA) in humans. "
5.	Neoplasms (Cancer) 01/01/2021 - "SHR0302 could prevent and reverse aGVHD in mouse models with preserving graft-versus-tumor effect. " 12/14/2019 - "Objective: To explore the effects and molecular mechanism of the selective JAK1inhibitor SHR0302 and Ruxolitinib on myeloproliterative neoplasms (MPN) cell line SET2 and primary cells in vitro. "

Related Drugs and Biologics

1.	ivarmacitinib
2.	Janus Kinase Inhibitors
3.	Janus Kinases
4.	Janus Kinase 1
5.	Therapeutic Uses
6.	ruxolitinib